26 terminated. 26 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Terminated 26 |
| Phase 2 | 11 | Terminated 11 |
Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intervention of Bladder Cancer by CAR-T 4SCAR-PSMA, 4SCAR-FRa - Bladder Cancer, Urothelial Carcinoma Bladder | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2025-08-01 | 2026-10-30 |
| A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer PF-07921585, Sasanlimab - Non Small Cell Lung Cancer, Bladder Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-11-11 | 2026-03-23 |
| Study of PF-07263689 in Participants With Selected Advanced Solid Tumors PF-07263689, Sasanlimab - Renal Cell Cancer, Melanoma | Phase 1 | Terminated | Pfizer | 13 | 2021-10-20 | 2024-04-12 |
| LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors Lerapolturev, 5% DDM - Solid Tumor, Bladder Cancer | Phase 1 / Phase 2 | Terminated | Istari Oncology, Inc. | 4 | 2021-08-01 | 2024-10-24 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers OC-001, Drug: OC-001 in Combination with Avelumab - Cancer, Neoplasms | Phase 1 / Phase 2 | Terminated | Ocellaris Pharma, Inc. | 73 | 2020-09-24 | 2026-01-12 |
| A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4. - Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer | Phase 1 / Phase 2 | Terminated | Genmab | 48 | 2020-07-15 | 2023-07-25 |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer SEA-TGT, sasanlimab, brentuximab vedotin - Non-small Cell Lung Cancer, Gastric Carcinoma | Phase 1 | Terminated | Seagen Inc. | 133 | 2020-05-29 | 2025-02-10 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors Nanrilkefusp alfa, Pembrolizumab - Thyroid Cancer, Renal Cell Carcinoma | Phase 1 | Terminated | SOTIO Biotech AG | 115 | 2019-06-13 | 2026-03-27 |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) Atezolizumab, Enfortumab Vedotin, Niraparib - Urothelial Carcinoma, Bladder Cancer | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 272 | 2019-06-01 | 2026-08-03 |
| A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors CCT301-59 - Solid Tumor, Soft Tissue Sarcoma | Phase 1 | Terminated | Shanghai PerHum Therapeutics Co., Ltd. | 9 | 2019-05-16 | 2024-10-28 |
| Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA] - Oncology, Solid Tumor | Phase 1 / Phase 2 | Terminated | 4D pharma plc | 63 | 2019-01-10 | 2023-06-01 |
| A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer Avelumab - Bladder Cancer, Metastatic Bladder Cancer | Phase 1 / Phase 2 | Terminated | Baylor College of Medicine | 1 | 2018-12-14 | 2020-08-24 |
| Study of ADCT-301 in Patients With Selected Advanced Solid Tumors ADCT-301, Pembrolizumab - Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer | Phase 1 | Terminated | ADC Therapeutics S.A. | 78 | 2018-11-09 | 2024-06-13 |
| Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy Nivolumab, Questionnaires - Bladder Cancer | Phase 1 | Terminated | M.D. Anderson Cancer Center | 1 | 2017-07-07 | 2018-05-24 |
| Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression ADCT-502 - Breast Cancer, Non Small Cell Lung Cancer | Phase 1 | Terminated | ADC Therapeutics S.A. | 21 | 2017-05-18 | 2021-02-01 |
| Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract B-701, Pembrolizumab - Bladder Cancer | Phase 1 | Terminated | Mark Pomerantz, MD | 1 | 2016-12-14 | 2017-06-27 |
| A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) Toca 511, Toca FC - Colorectal Cancer, Triple Negative Breast Cancer | Phase 1 | Terminated | Tocagen Inc. | 21 | 2016-07-01 | 2020-02-07 |
| Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants Atezolizumab, Bacille Calmette-Guérin - Bladder Cancer | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 24 | 2016-06-13 | 2021-10-28 |
| A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Combination of Varlilumab and Atezolizumab - Carcinoma, Renal Cell, Kidney Diseases | Phase 1 | Terminated | Celldex Therapeutics | 18 | 2015-10-01 | 2018-04-30 |
| Safety Study of MGD009 in B7-H3-expressing Tumors MGD009 - Mesothelioma, Bladder Cancer | Phase 1 | Terminated | MacroGenics | 67 | 2015-09-01 | 2022-02-08 |
Showing 20 of 26. Sign in to see all of them.
Urinary Bladder Neoplasms (26) · Carcinoma, Non-Small-Cell Lung (14) · Melanoma (11) · Carcinoma, Renal Cell (8) · Ovarian Neoplasms (8) · Triple Negative Breast Neoplasms (7) · Stomach Neoplasms (6) · Neoplasms (5) · Sarcoma (5) · Squamous Cell Carcinoma of Head and Neck (5) · Carcinoma, Transitional Cell (4) · Colorectal Neoplasms (4) · Head and Neck Neoplasms (4) · Pancreatic Neoplasms (4) · Uterine Cervical Neoplasms (4)
Female Urogenital Diseases (26) · Female Urogenital Diseases and Pregnancy Complications (26) · Male Urogenital Diseases (26) · Neoplasms by Site (26) · Urinary Bladder Diseases (26) · Urogenital Diseases (26) · Urogenital Neoplasms (25) · Urologic Diseases (25) · Urologic Neoplasms (25) · Neoplasms (21) · Neoplasms by Histologic Type (18) · Neoplasms, Glandular and Epithelial (17) · Carcinoma (16) · Bronchial Neoplasms (14) · Carcinoma, Bronchogenic (14)
pembrolizumab (5) · Cisplatin (3) · atezolizumab (3) · BCG Vaccine (2) · Gemcitabine (2) · avelumab (2) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · B701 protein, Human herpesvirus 6 (1) · Brentuximab Vedotin (1) · Carboplatin (1) · Cyclophosphamide (1) · DDMS (1) · Docetaxel (1) · Flucytosine (1) · Immunoglobulin G (1)
ADC Therapeutics S.A. (2) · Hoffmann-La Roche (2) · Pfizer (2) · 4D pharma plc (1) · Baylor College of Medicine (1) · Celldex Therapeutics (1) · Eisai Inc. (1) · Famewave Ltd. (1) · Genmab (1) · Heat Biologics (1) · Istari Oncology, Inc. (1) · M.D. Anderson Cancer Center (1) · MacroGenics (1) · Mark Pomerantz, MD (1) · Matthew Galsky (1)
United States (23) · Spain (5) · United Kingdom (4) · Canada (3) · France (3) · Belgium (2) · China (2) · Israel (2) · Australia (1) · Czechia (1) · Denmark (1) · Germany (1) · Greece (1) · Italy (1) · Netherlands (1)
Andres Forero-Torres, MD (1) · Deborah Bradley, MD (1) · Gary Steinberg, MD (1) · Jaime R Merchan, MD (1) · Jennifer M. Taylor, MD (1) · Lisa Franklin (1) · Lung-Ji Chang, PhD (1) · Mark Pomerantz, MD (1) · Matthew Campbell, MD (1) · Matthew D. Galsky, M.D. (1) · Roberto Oliveri, MD (1)
PMID 29322091, PMID 29735994, PMID 36803840, PMID 37651261
2019 (3), 2009 (1), 2018 (1)